Alimera Sciences To Release First Quarter 2014 Results

            Alimera Sciences To Release First Quarter 2014 Results

PR Newswire

ATLANTA, May 1, 2014

ATLANTA, May 1, 2014 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM)
("Alimera"), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced that it will release its first quarter of fiscal year 2014
financial results after the market close on Thursday, May 8, 2014. An investor
conference call will follow on the same day at 4:30 p.m. ET.

The conference call will be hosted by Dan Myers, President and Chief Executive
Officer, and Rick Eiswirth, Chief Operating Officer and Chief Financial
Officer.

To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or
(253) 237-1165 (international). A live webcast will be available on the
Investor Relations section of the corporate website at
http://www.alimerasciences.com.

A replay of the conference call will be available beginning May 8, 2014 at
7:30 p.m. ET and ending on May 16, 2014 by dialing (855) 859-2056 (U.S. and
Canada) or (404) 537-3406 (international), Conference ID Number: 41171987. A
replay of the webcast will also be available on the corporate website.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company that specializes in the research, development and
commercialization of prescription ophthalmic pharmaceuticals. Alimera's
European operations are conducted from London by its wholly-owned subsidiary,
Alimera Sciences Limited.

Investor Contact:

ICR, LLC

John Mills

310-954-1105

John.Mills@icrinc.com

SOURCE Alimera Sciences, Inc.

Website: http://www.alimerasciences.com
 
Press spacebar to pause and continue. Press esc to stop.